Open original FDA record ↗Recall record
- FDA identifier
- Z-1189-2024
- Company in FDA record
- Abbott Molecular, Inc.
- FDA classification date
- Feb 26, 2024
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class III
Reason stated in the source
Products that were intended for export only which were not approved or registered in accordance with U.S. specifications were shipped to U.S. customers.
Source facts
- Action
- The recalling firm issued letters dated and issued on 2/1/2024 via FedEx priority overnight express mail. The letter explained the background, potential impact, and necessary actions to be taken and contained an appendix listing Impacted Abbott Products and an appendix listing CE products and similar US products. The actions to be taken were to destroy all remaining inventory of the impacted products and contact their local Abbott representative for replacements. If the product has been forwarded to other laboratories, the consignee is requested to inform them of the recall and have them take the necessary actions. The letter states that laboratories should follow internal procedures in regard to a lookback of results and a lookback should be considered if results have been released that are tied to performance claims. A Customer Reply Form was enclosed to acknowledge receipt of the letter. The consignee was to record the amount of affected product that was destroyed.
- Initiated
- 2024-02-01
- Root cause
- Process control
- Distribution
- US Nationwide distribution in the states of AL, CA, IL, MA, MD, MN, NY, and PA.
- Recall number
- Z-1189-2024
- Recall status
- Open, Classified
- CDRH record ID
- 205983
- FDA classified
- 2024-02-26
- Recall event number
- 93902